Overview
- Applied Nutrition reported revenue of £161.6m and pre‑tax profit of £40.6m for the year to 31 July 2026, representing roughly 50% and 44% increases respectively.
- The company launched a dedicated GLP‑1 Friendly Range of products aimed at people using GLP‑1 weight‑loss medication, including protein shakes, creatine, liquid collagen pouches and digestive 'digest capsules'.
- Sales of the relaunched Critical Whey surged, increasing the group's exposure to whey protein and leaving margins sensitive to recent upward moves in whey‑protein input costs.
- Management said trading has been strong in the first quarter of 2026‑27 but it is holding formal guidance because significantly higher whey prices could reduce near‑term profitability; the board still targets about £49m underlying earnings and £205m sales for 2026‑27.
- The group has raised product prices to help offset raw‑material inflation and is relying on brand partnerships and high‑profile backers to broaden its customer base, a shift that brings more users of weight‑loss drugs into the sports‑nutrition market and may support continued category growth.